Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

Drugs

Volumn 54, Issue 2, 1997, Pages 331-354

  Adkins, Julie C ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; METHACHOLINE; SALBUTAMOL; SALMETEROL;

AEROSOL; ASTHMA; BRONCHOSPASM; CHILD; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRY POWDER; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAINTENANCE THERAPY; PEAK EXPIRATORY FLOW; REVIEW; SYMPTOM;

EID: 0030872326     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754020-00011     Document Type: Review

References (172)

1. Brogden RN, Faulds D. Salmeterol xinafoale: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Nov; 42: 895-912
2. Barbato A, Cracco A,Tormena F, et al. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Allergy 1995 Jun; 50: 506-10
3. Simons FER, Soni NR, Watson WTA, et al. Bronchodilalor and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immunol 1992 Nov; 90: 840-6
4. Verberne AAPH, Hop WCJ, Bos AB. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. J Allergy Clin Immunol 1993 Jan; 91: 127-34
5. Rhodes DG, Newton R, Butler R. et al. Equilibrium and kinetic-studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 1992 Oct. 42: 596-602
6. 2:-adrenergic receptor. J Biol Chem 1996 Sept; 271: 24029-35
7. Jack D. A way of looking at agonism and antagonism: lessons from sulbutamol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 1991 May; 31: 501-14
8. 2:-adrenoceptor agonist, salmeterol. Br J Pharmacol 1993 Feb: 108: 507-15
9. 2:-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol l996 Jan;49: 182-9
10. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992 Oct 22: 327: 1198-203
11. Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51:1100-4
12. Simons FER et al. A one-year placebo (P)-controlled study of the efficacy and safety of beclomethasone diproprionate (BDP) versus salmeterol xinafoate (SM) in glucocorticoidnaive children with asthma [ abstract no. 1634]. J Allergy Clin Immunol 1997 Jan; 99 ( 1 Pt 2): S402
13. Von Berg A, De Blic J, La Rosa M, et al. A comparison of regular salbutamol versus 'as required' salbutamol therapy in asthmatic children [abstract]. Am J Respir Crit Care Med 1996 (no. 4): A76
14. Von Berg A, De Blic J, La Rosa M, et al. A comparison of regular salmelerol versus 'a.s required' salbutamol therapy in asthmatic children. Glaxo Wellcome data on file 1996
15. Maconochie JG, Denyer LH, Hassani H. Dose-related protection against histamine-induced bronchoconstriction by inhaled salmeterol. Int J Clin Pharmacol Ther 1994 Jul: 32: 329-34
16. Faurschou P. Salmeterol and salbutamol: long-term efficacy and safety [abstract]. Eur Respir J 1992 Aug: 5 Suppl. 15. 317-8
17. Gongora HC. Wisniewski AFZ. Tattersfield AE, A single-dose comparison of inhaled albuterol and two formulations of salmelerol on airway reactivity in asthmatic subjects. Am Rev Respir Dis 1991 Sep; 144: 626-9
18. Derom EY, Pauwels RA, Van Der Staeten MEF, et al. The effect of inhaled salmelerol on methacholine re.sponsiveness in subjects with asthma up to 12 hours. J Allergy Clim lmmunol 1992 Apr; 89: 811-5
19. Rabe KF, Jörres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993 Jun; 147 (Pt 1): 1436-41
20. Zellweger JP, Pfenninger M, Ruff P, 24-Hour protective effect of salmeterol xinafoate (50 mcg ) versus formoterol (24 mcg) against methacholine-induced bronchoconstriclion in mild to moderate asthmatic patients. A randomized, double-blind, cross-over, single-dose trial [abstract]. Eur Respir J 1994; 7 Suppl. 18: 422s
21. 2: agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993 Nov; 48: 1121-4
22. Nowak D, Jörres R, Rabe KF, et al. Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. Eur J Clin Pharmacol 1992 Dec; 43: 591-5
23. Malo J-L, Ghezzo H, Trudeau C, Salmeterol, a new inhaled beta2-adrenergic agonist, has a longer blocking eltect than albuterol on hyperventilation-induced bronchoconstriclion. J Allergy Clin Immunol 1992 Feb; 89: 567-74
24. Cartier A. Ghezzo H, L'Archevêque J, et al. Duration and magnitude of action of 50 and 100 μg of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma. J Allergy Clin Immunol 1993 Sep; 92: 488-92
25. Gong Jr H, Linn WS, Shamoo DA. et al. Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects. Chest 1996 Nov; 110: 1229-35
26. Verberne AAPH, Hop WCJ. Creyghlon FBM, et al. Airway responsiveness afler a single dose of salmeterol and during four months of treatment in children wilh asthma. J Allergy Clin Immunol 1996 Apr; 97. 938-46
27. Meijer GG, Postma DS, Mulder PGH, et al. Long-term circadian effects of salmeterol in asthmatic children treated wilh inhaled corticosleroids. Am J Respir Crit Care Med 1995 Dec: 152 (Pt 1): 1887-92
28. Bhagat R, Kalra s, Swystun VA, et al. Rapid onset of tolerance to the bronchoproteclive effect of salmeterol. Chest 1995 Nov; 108: 1235-9
29. Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996 Apr: 109: 953-6
30. 2-agonist. Am J Respir Crit Care Med 1996; 154: 1603-7
31. Verberne AAPH. One year treatment wilh salmeterol compared to inhaled corticosteroid in children with mild to moderate asthma [abstrac]. Am J Respir Crit Care Med 1996 (no. 4): A408
32. Verberne AAPH, Frost C, Bogaard JM, et al. One year treatment with salmeterol compared to inhaled corticosteroid in children with mild to moderate asthma. Glaxo Wellcome data on file. 1996
33. Verberne AAPH, McCorrnack F.M, Fuller R. et al. An overview of nine clinical trials of salmelerol in an asthmatic population [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 156s
34. Rosenthal R, Chervinsky P, DeGraff A, et al. Long term, regular treatment with salmeterol is effective in protecting against bronchial hyperresponsiveness as measured by methacholine challenge in asthmatics [abstract no. 1322]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): S323
35. Cracco G, Dal, Negro R, Boer LA. et, al. Salmelerol (50 mcg bid) versus nedocromil (4 mg tid): protective effect against hyperreaclivily to ultrasonically nebulised distilled water in asthmatic children. Riv Ital Pediatr 1995 Dec; 21: 807-12
36. Hough DO, Dec KL. Exercise-induced asthma and anaphylaxis. Sports Med 1994 Sep: 18: 162-72
37. National Heart Lung and Blood lnstilule. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 1991 Sept; 88: 519-22
38. Weiler JM. Exercise-induced asthma: a practical guide to definitions, diagnosis, prevalence, and treatment. Allergy and Asthma Proceedings 1996 Nov-Dec; 17: 315-25
39. Carlsen K-H. Roksund O, Olsholt K, et al. Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Eur Respir J 1995 Nov; 8: 1852-5
40. Cavallo A, Cassaniti C, Magrini H. et al. The effect of sulmeterol on exercise-induced asthma [abstract]. J Allergy Clin Immunol 1995 Jan: 95 (Pt 2): 354
41. Clark RA, Reid PC, Taak NK. A comparison of the duration of protection against exercise induced bronchoconstriction following single and chronic dosing with salmeterol and sodium cromoglycale in children [abstract]. Eur Respir J 1995 Sep: 8 Suppl. 19: 517s
42. de Benedictis FM, Tuteri G. Pazzelli P, et al. Salmeterol in exercise-induced bronchoconstriction in asthmalic children: comparison of two doses. Eur Respir J 1996 Oct: 9: 2099-103
43. Ferrés J, Castro E, Guasch E. et al. Salmeterol in exercise induced asthma in children with different degrees of severity 5 hours prior to a running tesl [abstract]. Eur Respir J 1995 Sep: 8 Suppl. 19: 518
44. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992 Aug; 67: 1014-7
45. Langton Hewer S, Hobbs J, Connett G, et al. Salmeterol in the prevention of exercise-induced bronchospasm in preschool children [abstract]. Eur Respir J 1994; 7 Suppl. 18: 451
46. Simons FER, Getstner TV, Cheng MS, et al. Tolerance to the hronchoprotective effect of salmetcrol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997 May; 99: 655-9
47. Tsanakus J, Gomez E. The duration of protection against exercise-induced bronchoconstriction following single dosing with salmeterol 50mcg via the Diskus and sodium cromoglycale 20mg via the Spinhaler in children 6-11 years with asthma. Joint Meeting of the European Society of Pediatric Allergy and Clinical Immunology (ESPACI) and the European Respiratory Society Pediatric Assembly: 1996 May 22-25; Odense. Denmark, 69
48. Newnham DM, Ingram CG, Earnshaw J. et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med 1993 Aug; 87: 439-44
49. Sichletidis L, Daskalopoulou E, Kyriazis G. et al. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. J Int Med Res 1993 Mar-Apr; 21:81-8
50. Schaanning J, Vilsvik J, Henriksen AH. Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconslriction. Ann Allergy Asthma Immunol 1996 Jan; 76: 57-60
51. Kemp JP, Dockhorn RJ. Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm Am J Respir Crit Care Med 1994 Dec; 150 (Pt 1): 1612-5
52. Ramage L, Lipvvorth BJ, Ingram CG. Reduced protection against exercise induced bronchoconstriction alter chronic dosing with salmeterol. Respir Med 1994 May; 88: 363-8
53. 2:-agonist, on IGE-mediated histamine release from human leukocytes [abstract]. Allergy 1992; 47 (12) Suppl.: 229
54. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammalory mediator release from human lung. Br J Pharmacol 1991 Nov: 104: 672-6
55. 2-adrenoceptor agonists on mast cells of rat, guinea pig, and human. Int Arch Allergy Immunol 1994 Oct; 105: 177-80
56. Gentilini G, Grazia Di Bello M, Raspanti S, et al. Salmeterol inhibits anaphylactic histamine release from guinea-pig isolated mast cells. J Pharm Pharmacol 1994 Jan: 46: 76-7
57. 2-adrenergic agonists on isolated guinea pig lung mast cells. Agents Actions 1994 Oct; 42: 92-4
58. Baker AJ. Palmer J, Johnson M. et al. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. Eur J Pharmacol 1994 Nov 3; 264: 301-6
59. 2agonists: a comparison of salbutamol and salmeterol [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 547s
60. Pennings HJ, Dentener MA. Buurman WA, et al. Salbutamol and salmeterol modulate cytokine production by peripheral blood monocytes [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 377s
61. Sekut L, Champion BR, Page K, et al. Anti-inflammatory activity of sulmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995 Mar: 99: 461-6
62. Lapa e Silva JR. Ruffië C, Pretolani M, et al. Effect of salmeterol on antigen-induced T-lymphocyte and eosinophil recruitment to airways of sensitized guinea pigs [abstract]. Allergy 1996; 51 Suppl. 30: 80
63. Oddera S, Silvestri M, Testi R, et al. Salmeterol enhances in vitro the inhibitory effects of dexamethasone on allergen-induced T-lymphoctye activation, partially suppressing the release of GM-CSF and TNF-α [abstract]. Eur Respir J 1994; 7 Suppl. 18:468
64. Whelan CJ. Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 1992 Apr; 105: 831-8
65. Whelan CJ, Johnson M, Vardey CJ. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993 Oct; 110:613-8
66. Vardey CJ, Colemun RA, Johnson M. et al. Inhibition of LPS-induced neutrophil accumulation in rat lung by salmeterol: positive interaction with dexamethasone [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 362
67. Hyers TM, Tricomi SM. Salmeterol shows anti-inflammatory effects on human neutrophils in vitro [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 804
68. Radermecker MF, Louis R. Corhay JL. et al. Effect of salmeterol, theophylline and nedocromil sodium on neutrophit chemotaxis in man [abstract]. Allergy 1992; 47 (12) Suppl.: 48
69. Ottonello L, Morone P, Dapino P, et al. Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Clin Exp Immunol 1996 Oct; 106: 97-102
70. Vardey CJ, Nials AT, Coleman RA. Inhibitory effects of salmeterol in human neutrophils are short-lasting [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 361
71. 4 by human eosinophils. Eur Respir J 1996 Aug; 9 Suppl. 22: 141s-5s
72. Oddera S, Silvestri M, Lantero S, et al. Salmeterol downregulates in vitro GM-CSF and IL-5 release and LFA-1 expression on T-cells [abstract]. Allergy 1996; 51 Suppl. 31: 33
73. Muǹoz NM, Rabe KF, Vita AJ. et, al. Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther 1995 May; 273: 850-4
74. Rabe KF, Giembycz MA, Dent G. et al. Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993 Feb 9; 231: 305-8
75. 2:-adrenoceptors mediate a reduction in endothelial permeability in vitro. Eur J Pharmacol 1995 Feb 14:274: 7-15
76. Twentyman OP, Finnerty JP, Harris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990 Dec 1; 336:1338-42
77. 4 excretion. J Allergy Clin Immunol 1992 Feb; 89: 575-83
78. Pedersen B, Dahl R, Larsen BB. et al. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 1993 Jul; 48: 377-82
79. Weersink EJM, Aalbers R, Koëter GH, et al. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am J Respir Crit Care Med 1994 Nov. 150(Pt 1 ): 1262-7
80. Pizzichini MMM, Kidney JC, Wong BJO. et al. Effect of salmeterol compared with beclomethasone on allergeninduced asthmatic and inflammatory responses. Eur Respir J 1996 Mar; 9: 449-55
81. Boulet L-P, Turcotte H, Boulet M, et al. Influence of salmeterol on chronic and allergen-induced airway inflammation in mild allergic asthma: a pilot study. Curr Ther Res 1997 April; 58 (4): 241-59
82. Lebel B, Arnoux B, Chanez P, et al. Ex vivo pharmacologic modulation of basophil histamine release in asthmatic patients. Allergy 1996 Jun: 51: 394-400
83. O'Connell F, Birchall M, Studham J, et al. The effect of topical salmeterol, salbutamol and placebo on intranasal histamine and allergen challenge [abstract]. Eur Respir J 1994; 7 Suppl. 18: 236s
84. Ramage L, Cree IA, Dhillon DP. Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels. Int Arch Allergy Immunol 1994 Oct: 105: 181-4
85. Michel O, Olhrecht J, Moulard D, et al. Effect of salmeterol on blood markers of inflammation induced by LPS inhalation [abstract], Int Congr Allergol Clin Immunol 1994 Suppl. 2: 52
86. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994 Oct; 150: 1006-11
87. Rocheleau H, Lavigne S, Turcotte H, et al. Effects of salmeterol on the production of leukotriene C4 by blood eosinophils [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 115
88. Devalia JL, Sapsford RJ, Rusznak C, et al. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulmon Pharmacol 1992 Dec: 5: 257-63
89. Kaspar P, Petro W, Pollano F. Ciliary beat frequency (BF) of human nasal epithelial (HNE) cells from asthma patients under salbutamol (SB) and salmeterol (SM) in vitro [abstract]. Am J Respir Crit Care Med 1994 Apr: 149 (Pt 2): A804
90. Kanthakumar K, Cundell DR, Johnson M, et al. Efftect of salmeterol on human nasal epithelial cell ciliary heating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol 1994 Jun: 112:493-8
91. Dowling RB, Rayncr CFJ, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997; 155: 327-36
92. James MH, Johnson M. Effect of salmeterol on respiratory tract infections [abstract no. P1676]. Eur Respir J 1996 Sept; 9 Suppl. 23: 264s
93. Glaxo Wellcome Data on File. Serevcnt inhalation aerosol data sheet 1996
94. Manchee GR, Barrow A, Kulkarni S, et al. Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metah Dispos 1993 Nov-Dec; 21: 1022-8
95. Manchee GR, Eddershaw PJ, Ranshaw LE. et al. The aliphatic oxidation of salmeterol to α-hydroxysalmelerol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 1996 May; 24: 555-9
96. Gustafsson PM, von Berg A, Jenkins MM. Salmeterol 50 μg twice daily in the treatment of mild-to-moderate asthma in childhood - a comparison of two inhalation devices. Eur J Clin Res 1994: 5: 63-73
97. Kurihara K, Mikawa H, Baba M, et al. Clinical study of salmeterol xinafoate (SN408) dry powder - comparative study between salmeterol xinafoate aerosol in children with bronchial asthma [in Japanese]. Rinsho lyaku 1993; 9 (10): 2473-87
98. Nishima S, Odujima H, Origasa H, Clinical study of salmeterol xinafoate (SN408) dry powder - bioequivalency study between salmeterol xinafoate aerosol in children with bronchial asthma by single dose crossover method [in Japanese], Rinsho lyaku 1993; 9 (9): 2133-46
99. Bishop AL, Chervinsky P, Liddle R, et al. Salmeterol xinafoate for treatment of reversible obstructive airways disease in children [abstract]. J Allergy Clin Immunol 1994 Jan; 93 (Pt 2): 248
100. Verberne A, Lenney W, Kerrebijn K. A 3 way crossover study comparing twice daily dosing of salmeterol 25mcg and 50mcg with placebo in children with mild to moderate reversible airways disease [abstract]. Am Rev Respir Dis 1991 Apr: 143 Suppl. 2: 20
101. Lenney W, Pedersen S. Boner AL, et al. Efficacy and safely of salmeterol in childhood asthma. Eur J Pediatr 1995 Dec; 154: 983-90
102. Byrnes CA, Weher EA, Moorat A, et al. A comparison of salmeterol xinafoate ( 50mcg bd and 100mcg bd) with salbutamol 200mcg qds in paediatric asthma [abstract]. Am J Respir Crit Care Med 1996; 153 (no. 4): A408
103. Pearlman DS, Bronsky E, Chervinsky P, et al. Inhaled salmeterol powder compared with placebo administered over 12 weeks to children with mild-to-moderate asthma [abstract], Am J Respir Crit Care Med 1996; 153 (no. 4): A76
104. Götz MH, Taak NK. The efficacy and safety of inhaled salmeterol xinafoate (50mcg bd) compared with salbutamol (200mcg prn) in children with asthma [abstract no. P2543]. Eur Respir J 1995 Sep; 8 Suppl. 19: 517s
105. 2:-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol 1995 Aug; 75: 180-4
106. D'Alonzo GH, Nathan RA, Henochowicz. S, et al. Salmeterol xinafoate as maintenance therapy compared with alhuterol in patients with asthma. JAMA 1994 May 11; 271: 1412-6
107. Pcurlman DS. Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-mojerate asthma. N Engl J Med 1992 Nov 12; 327: 1420-5
108. Lundhack B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993 Feb; 48: 148-53
109. Britton MG, Earnshaw JS, Palmer JBD, et al. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992 Oct 5: 1062-7
110. Paggiaro PL, Giannini D, Di Franco A. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction, Eur Respir J 1996 Aug; 9: 1689-95
111. Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994 Sep; 88: 599-607
112. Davies BH, Tibbetts HA, Brooks GM, et al. The efficacy and safely of salmeterol compared to theophylline: a meta-analytic integration of nine controlled studies [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 262s
113. Spector S, Pleskow WW, Goldslein MF, et al. Salmeterol compared with theophylline in the treatment of asthma [abstract]. Asthma Theory to Treatment; 1995 July 15-17; Chicago. Illinois, USA, 11
114. Bucca C, Rolla G, Brussino L, et al. Inhaled salmeterol versus oral ketotifen in mild-to-moderate asthma. Eur J Clin Res 1995: 7: 57-71
115. Johnson ME, UK Study Group. A multieentre study to compare the efficacy and safety of salmeterol xinafoate and nedoeromil sodium via metered-dose inhalers in adults with mild-to-moderate asthma. Eur J Clin Res 1994; 5: 75-85
116. Venables T. A multicentre study in general practice to comparethe efficacy and tolerability of inhaled salmeterol xinafoate and terbutuline in the treatmenl of asthma. Br J Clin Res 1992; 3: 125-36
117. Bousquet J, Aubert B, Bons J. Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Ann Allergy Asthma Immunol 1996 Feb; 76: 189-94
118. British Asthma Guidelines Coordinating Committee. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997 Feb: 52 Suppl. 1: S1-21
119. National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. (USA). Bethesda: NHLBI Information Centre. 1997
120. Russell G. Williams DAJ, Weller P, et al. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995 Nov; 75: 423-8
121. Langton Hewer S, Hobbs J, French D, et al. Pilgrim's progress. the effect of salmeterol in older children with chronic severe asthma. Respir Med 1995 Jul; 89: 435-40
122. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled eorticosteroid. Lancet 1994 Jul 23; 344: 219-24
123. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996 May; 153: 1481-8
124. Du-Buske L, Cox F, Bowers B, et al. Salmeterol (42 μg bid) improves clinical outcomes in adolescents and adults with nocturnal asthma [abstract no. 1327]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): S325
125. Muir JF, Bertin L, Georges D. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 1992 Nov; 5: 1197-200
126. 2-agonist. BMJ 1990 Dec; 301: 1365-8
127. Brambilla C, Chastang C, Georges D. et al. Salmeterol compared with slow-release terbutaline in nocturnal asthma: a multicenter, randomized, double-blind, double-dummy, sequential clinical trial. Allergy 1994 Jul; 49: 421-6
128. Faurschou P, Engel A-M, Haanaes OC. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994 Dec; 49: 827-32
129. 2 agonists and their safety in the treatment of asthma. Allergy Proc 1995 Sep-Oct; 16: 235-9
130. 2-agonists in the management of asthma. Drug Saf 1992 Jan-Feb; 7: 54-70
131. Peters DH, Faulds D, Salmeterol: an appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma. PharmacoEconomics 1995 Jun; 7: 562-74
132. Rutten-van Mölken MPMH, Custers F, Van Doorslaer EKA, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995 Jun; 8: 888-98
133. Juniper EF, Johnston PR, Borkhoff CM, et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995 Jan; 151:66-70
134. Hyland ME, Kenyon CAP, Jacobs PA. Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics. Qual Life Res 1994 Apr; 3: 121-6
135. Charpin D, Vervloet D. Quality of life in moderate chronicasthma: salmeterol versus current treatments [abstract]. Allergy 1992; 47 (12 Suppl.): 230
136. Goodwin R, Cox F, Lumry W, et al. The impact of salmeterol versus albuterol on disease specific quality of life in mild to moderate asthmatics [abstract]. J Allergy Clin Immunol 1996 Jan; 97 (Pt 3): 256
137. De Carli G, Arpinelli F, Irvine SH, et al. Change of quality of life induced by salmeterol and salbutamol in adult asthmaticpatients [abstract no. 118]. Therapie 1995; 50 Suppl.
138. Arpinelli F, De Carli G, Irvine SH, et al. Effects of salmeterol and nedocromil on quality of life in mild to moderate asthmatic patients [abstract], Therapie 1995; 50 Suppl.: 144
139. Bowers BW, Cox FM, Kalberg C. et al. The impact of salmeterol on asthma-specific quality of life in patients reporting nocturnal awakenings due to asthma [abstract no. P32]. Ann Allergy Asthma Immunol 1997 Jan; 78: 110
140. French DJ, Christie MJ, Sowden AJ. The reproducibility of the Childhood Asthma Questionnaires: measures of quality of life for children with asthma aged 4-16 years. Qual Life Res 1994; 3:215-24
141. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992 Mar: 33: 342-5
142. 2 adrenoceptor agonist: comparison with salhutamol in adult asthmatic patients. Thorax 1988; 43: 674-8
143. Sauer MJ, Graham PJ, Lake BG, et al. Metabolism of the betaagonists clenbuterol, salhutamol and salmeterol by microsomes, hepatocytes and precision-cul slices prepared from bovine liver [abstract]. Hum Exp Toxicol 1996 Feb; 15: 150
144. Swearingen BE, Burke GL, Rickard KA. Salmeterol sale compared to current treatments as measured by electrocardiography [abstract no. 1333]. J Allergy Clin Immunol 1997 Jan; 99 (Pt2):S326
145. Tunaoglu S, Turklas I, Oguz D, et al. Cardiac side effects of long acting beta-2 agonist salmeterol in asthmatic children [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 517s
146. Pollard SJ, Bronsky EA, Chervinsky P. et al. The safety of salmeterol in pediatric patients as assessed by 24-hour electrocardiogram monitoring [abstract]. Am J Respir Crit Care Med 1994 Apr: 149 (Pt 2): 350
147. Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15.407 patients. J Clin Epidemiol 1996 Feb; 49: 247-50
148. Clark CE. Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993 Apr: 87: 227-8
149. Sims TA, Thomas TV, Plattenburg PD, et al. Salmeterol xinafoate induced fatal respiratory arrest, Int Pharm Ahstr 1995 Nov 15; 32: 2325
150. Finkelstein FN. Risks of salmeterol? [letter]. N Engl J Med 1994 Nov 10; .331: 1314
151. Shale DJ. Respiratory arrests in young asthmatics on salmeterol [letter: comment]. Respir Med 1994 Jan; 88: 75-6
152. Palmer JBD. Rickard KA, Thompson JR. Risks of salmeterol? Glaxo, the manufacturer of salmeterol, replies [letter]. N Engl J Med 1994 Nov 10: 331: 1314
153. Skorodin MS. Asthma mortality and β-agonists [letter]. Chest 1995 Dec; 108: 1768
154. Devoy MAB, Fuller RW, Palmer JBD. Asthma mortality and beta-agonists. Reply [letter]. Chest 1995 Dec; 108: 1768
155. Munro NC. Respiratory arrests in young asthmatics on salmeterol [letter; comment]. Respir Med 1993 Nov; 87: 638-9
156. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance sludy: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993 Apr 17; 306: 1034-7
157. 2-agonisls in the treatment of asthma? Chest 1995 Apr; 107: 1116-24
158. AAAAI Committee on Drugs. Safety and appropriate use of salmeterol in the treatment of asthma. J Allergy Clin Immunol 1996 Sep; 98: 475-80
159. Fuller R. Safety of salmeterol in the treatment of asthma. Eur Resp Rev 1995 May: 5 Rev. 27: 133-7
160. Management of asthma in the community [editorial]. Lancet 1989 July; II: 199-200
161. Office of Health Economics. Asthma. London: OHE. 1990
162. Wilkinson JRW, Roberts JA, Bradding P. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992 Oct 17; 305: 931-2
163. Shaheen MZ, Ayres JG, Benincasa C. Incidence of acute decreases in peak expiratory flow following the use of meteredhalers in asthmatic patients. Eur Respir J 1994 Dec: 7: 2160-4
164. Glaxo Wellcome. Salmeterol prescribing informatiom. Ux-bridge. UK
165. Paton J. The safety of inhaled steroids in childhood asthma. Practitioner 1994 Apr; 238: 322-6
166. Boner AL, Piacentini GL. Inhaled corticosteroids in children: is there a 'safe' dosage? Drug Saf 1993 Jul; 9: 9-20
167. Foucard T. Aggressive treatment of childhood asthma with local steroids. Good or bad? Allergy 1996 Jun; 51: 367-71
168. Price JF. Asthma, growth and inhaled corticosteroids. Respir Med 1993 Feb; 87 Suppl. A: 23-6
169. Kamada AK. Szefler SJ, Martin RJ, et al. Issues in the use of inhaled corticosteroids. Am J Respir Crit Care Med 1996 Jun; 153 (Pt 1). 1739-48
170. Kamada AK, Szefler SJ. Glucoeorticoids and growth in asthmatic children. Pediatr Allergy Immunol 1995 Aug; 6: 145-54
171. McGill KA, Joseph B, Busse WW. Cortieosteroids in the treatment of asthuma: practical recommendations. Clin Immunother 1945 Jul; 4: 16-48
172. Wilding P, Clark M, Thompson J, et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997 May; 314: 1441-6